⌕

Evidence-graded drug-asset intelligence

Therapeutic area

Ophthalmology

Diseases and disorders of the eye, retina, and visual system.

Diseases

Age-Related Macular Degeneration

$486.2B attributable cost

$9.7B drug spend

33 assets · 1 indication

All assets in Ophthalmology

Company

AbbVie (3)Amgen (2)Annexon, Inc. (2)Astellas Pharma (1)Bausch Health (1)Bio-Thera Solutions (1)Biocon (1)Biogen (1)Boehringer Ingelheim (2)Celltrion (1)Chong Kun Dang Pharmaceutical (1)Formycon AG (1)Harrow, Inc. (3)Kodiak Sciences Inc. (3)Lupin Limited (1)Mabwell (Shanghai) Bioscience Co., Ltd. (1)Novartis (2)OCULAR THERAPEUTIX, INC (2)Pfizer (1)Regeneron Pharmaceuticals (3)REGENXBIO Inc. (2)RemeGen Co., Ltd. (1)Roche (2)Sandoz Group AG (2)Sanofi (2)Shanghai Henlius Biotech (1)Zydus Lifesciences (1)

33 of 33 assets

ABBV-6628

Antibody fragmentPhase 2

ABBV-RGX-314

Gene therapy / editingPhase 3

ABP 938

Protein / enzyme therapeuticPhase 3

Aflibercept · Eylea

Protein / enzyme therapeuticApproved

ANX007

Monoclonal antibodyPhase 3

Avacincaptad pegol · Izervay

OtherApproved

BAT5906

Monoclonal antibodyPhase 3

BI 1584862

Unknown / undisclosedPhase 2

BI 771716

Antibody fragmentPhase 2

Brolucizumab-Dbll

Antibody fragmentApproved

Cemdisiran

RNA / oligonucleotidePhase 3

chloroprocaine

Small molecule

CKD-701

Biologic — subtype unspecifiedPhase 3No recent activity

faricimab

Monoclonal antibodyApproved

HLX04-O

Monoclonal antibodyPhase 3

KSI-301

Unknown / undisclosedPhase 3

MW02

Monoclonal antibodyPhase 3

OTX-TKI

Small moleculePhase 3

OTX-TKI (axitinib implant)

Small moleculePhase 3

Pegaptanib Sodium 0.3 mg

Unknown / undisclosedApproved

Pegcetacoplan ophthalmic · Syfovre

PeptideApproved

Pozelimab

Monoclonal antibodyPhase 3

Ranibizumab · Lucentis

Monoclonal antibodyApproved

RC28-E

Protein / enzyme therapeuticPhase 3

RGX-314

Gene therapy / editingPhase 3

SAR402663

Gene therapy / editingPhase 2

SAR446597

Gene therapy / editingPhase 2

Surabgene Lomparvovec (ABBV-RGX-314)

Gene therapy / editingPhase 3

Tabirafusp tedromer

Multispecific antibodyPhase 3

Tarcocimab tedromer

Monoclonal antibodyPhase 3

Verteporfin

Small moleculeApproved

Visudyne

Small moleculeApproved

Vonaprument

Antibody fragmentPhase 3

← all areas

BrowseAll assets All companies Readout calendar

ReferenceMethodology & sources Us vs. the AI tools Report a problem / suggest a feature

Stay updated

Occasional update emails, nothing else. Unsubscribe is one reply.

Educational research only, not investment advice. Evidence quality is graded; securities never are. · Terms · Privacy · Logos by Logo.dev

Company

AbbVie (3)Amgen (2)Annexon, Inc. (2)Astellas Pharma (1)Bausch Health (1)Bio-Thera Solutions (1)Biocon (1)Biogen (1)Boehringer Ingelheim (2)Celltrion (1)Chong Kun Dang Pharmaceutical (1)Formycon AG (1)Harrow, Inc. (3)Kodiak Sciences Inc. (3)Lupin Limited (1)Mabwell (Shanghai) Bioscience Co., Ltd. (1)Novartis (2)OCULAR THERAPEUTIX, INC (2)Pfizer (1)Regeneron Pharmaceuticals (3)REGENXBIO Inc. (2)RemeGen Co., Ltd. (1)Roche (2)Sandoz Group AG (2)Sanofi (2)Shanghai Henlius Biotech (1)Zydus Lifesciences (1)

33 of 33 assets

ABBV-6628

Antibody fragmentPhase 2

ABBV-RGX-314

Gene therapy / editingPhase 3

ABP 938

Protein / enzyme therapeuticPhase 3

Aflibercept · Eylea

Protein / enzyme therapeuticApproved

ANX007

Monoclonal antibodyPhase 3

Avacincaptad pegol · Izervay